We encourage you to join the XLHED Network (www.xlhednetwork.com).
The XLHED Network is dedicated to patients and families affected by Hypohidrotic Ectodermal Dysplasia (HED) or X-linked HED (XLHED) and their healthcare providers. Members of our network benefit from informative updates on HED and XLHED research and upcoming clinical trials sponsored by Edimer Pharmaceuticals.
To join the XLHED Network, please follow this link www.xlhednetwork.com to complete the confidential form — it will take approximately five minutes to complete.
Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrodic Ectodermal Dysplasia (XLHED).
XLHED is a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisors. The company is based in Cambridge, Massachusetts.